Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Collaboration › Details

Deerfield–Duke Univ: translational research, 201912–2029 collab establishm Four Points Innovation up to $130m from Deerfield to finance Duke projects

 

Period Period 2019-12-18 ï¿½ 2029-12-31
Organisations Partner, 1st Four Points Innovation (US)
  Group Deerfield (Group)
  Partner, 2nd Duke University, Office of Licensing & Ventures (OLV)
  Group Duke University
Products Product translational medicine / translational research
  Product 2 venture capital
Person Person Flynn, James E. (Deerfield Management 201909 Managing Partner)
     

Deerfield Management Company L.P.. (12/18/19). "Press Release: Duke University and Deerfield Management Announce Four Points Innovation". Durham, NC & New York, NY.

Deerfield Commits up to $130 million to Accelerate Drug Discovery at Duke Through a Newly Launched Company


Duke University and Deerfield Management Company, a healthcare investment firm, today announced the creation of a major translational research collaboration. Spearheaded by Duke University’s Office of Licensing & Ventures (OLV), the alliance is expected to accelerate the preclinical development of new drugs for improved quality of life and cures for disease.

“This is an exciting day for Duke and the patients we serve,” said Mary E. Klotman, MD, Dean, Duke University School of Medicine and Vice Chancellor for Health Affairs. “This new partnership will help further Duke’s commitment to improve the lives of people in our own community and around the world by supporting and accelerating the translation of research into new therapies to treat and cure society’s most formidable healthcare challenges.”

By way of a newly launched company called Four Points Innovation, up to $130 million of initial funding will be made available by Deerfield to back the initiative for 10 years. Deerfield also will provide development expertise in support of Duke’s innovative drug research across a span of high-need therapeutic areas, as well as those targeting patients who suffer from hard-to-treat and rare diseases.

A private company wholly owned by affiliates of Deerfield, Four Points Innovation will support Duke R&D projects throughout preclinical stages of drug discovery and development. Beginning approximately in March 2020, Duke researchers will have the ability to submit proposals on projects for consideration by a Four Points Innovation committee comprised of scientific leadership representing both Duke and Deerfield. ?

Accepted projects will include a development plan aimed at achieving Investigational New Drug (IND) readiness. Deerfield will provide funding and operational support for accepted projects, and successful projects that achieve IND-enabled status may be eligible for additional capital from Deerfield.

Duke’s Office of Licensing and Ventures broke previous records last year with 354 invention disclosures, 120 agreements, and 32 exclusive agreements. Duke faculty and staff formed sixteen new start-up companies during the year, bringing the university’s total to over 140 new companies. Over the last two years, 29 of the university’s 32 start ups have chosen to stay in North Carolina.

“Duke University, with its vast research enterprise, world-class investigators and novel innovations, is a leader in biomedical discovery,” said James E. Flynn, Managing Partner at Deerfield Management. “We are excited about entering into this partnership with Duke, as we collectively seek to develop new medicines to save lives and address unmet medical needs.”

Under the terms of the agreement, Four Points Innovation would receive an option to license Four Points Innovation-funded intellectual property developed at Duke.


About Duke University

Duke is a private research university in Durham, N.C. with nearly 16,000 undergraduate, graduate, and professional students and a world-class faculty helping to expand the frontiers of knowledge. The Duke School of Medicine is one of the nation’s leading centers for medical education, clinical care and biomedical research.


About Deerfield Management

Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy.


Contacts

Michael Schoenfeld, michael.schoenfeld@duke.edu, (919) 681-3788
Karen Heidelberger, karenh@deerfield.com, 212-551-1600

   
Record changed: 2020-01-03

Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 650x65px

More documents for Deerfield (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top